poisar

Stocks · News reference

Firefly Neuroscience And Next Health Partner To Launch Precision Cognitive Health Platform Integrating Firefly’s AI-Powered, FDA-Cleared EEG/ERP Brain Biomarker Technology With Personalized Cognitive Peptide Protocols

Jul 28, 2026, 11:52 AMBenzinga Newsdesk

– FDA Advisory Committee voted to recommend easing compounding restrictions for six peptides, including Epitalon and Semax, late last week – – These two peptides have attracted growing scientific interest for their

Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

AIFF
Source
benzinga
Observed
Jul 28, 2026, 11:52 AM
Checked
Jul 28, 2026, 11:52 AM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Aug 7, 2026, 8:30 PMSEC EDGAR

    8-K filing — FIREFLY NEUROSCIENCE, INC. (AIFF)

    Filed: 2026-08-07 AccNo: 0001213900-26-086720 Size: 231 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 5.07: Submission of Matters to a Vote of Security Holders Item 9.01: Financial Statements and Exhibits

    Read original at edgar
    AIFF
  2. Aug 5, 2026, 11:45 AMNa

    Firefly Neuroscience (NASDAQ: AIFF) Reports 291% Increase in TMS Center Customer Brain Scan Volumes

    Firefly Neuroscience announced a nearly four-fold increase in TMS center customer clinical assessments using its FDA-cleared Evoke AI-powered EEG/ERP platform. The platform combines quantitative EEG and event-related potentials to help clinicians assess brain activity and tailor treatments for psychiatric and behavioral health conditions. The company continues to expand adoption among TMS centers while building its proprietary database of over 200,000 EEG/ERP brain scans.

    Read original at globenewswire-inc
    AIFF
  4. Jul 28, 2026, 11:50 AMNa

    Firefly Neuroscience (NASDAQ: AIFF) and Next Health Launch Precision Cognitive Health Initiative as FDA Advisory Committee’s Recommendation Backs Broader Access to Key Neuroprotective Peptides

    Firefly Neuroscience (NASDAQ: AIFF) and Next Health announced a strategic partnership to launch a precision cognitive health platform combining Firefly's FDA-cleared AI-powered EEG/ERP brain biomarker technology with personalized cognitive peptide protocols. The collaboration follows an FDA Advisory Committee's recommendation to ease compounding restrictions for six peptides, including Epitalon and Semax, which have shown potential neuroprotective and cognitive-supportive properties in scientific literature.

    Read original at globenewswire-inc
    AIFF